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Purpose of the study
Apricitabine (ATC) is a novel cytidine analogue NRTI with
promising activity and safety in the treatment of HIV-1
infected patients with resistance to other NRTIs. AVX-201
is a 48-week Phase IIb study of ATC compared to lamivu-
dine (3TC) in treatment-experienced patients with
M184V. Previously reported data at 24 weeks showed a
greater proportion of patients reaching an undetectable
viral load and greater increases in CD4 cells with ATC
compared to 3TC. At 24 weeks, patients in the 3TC arm
switched to ATC; final week 48 data are presented here.
Methods
HIV-1 infected patients with M184V were randomised to
receive twice daily 600 mg ATC, 800 mg ATC or 150 mg
3TC for 24 weeks, with background antiretroviral therapy
(ART) optimised according to genotype on Day 21. From
week 24, all patients received open-label ATC (800 mg
BID).
Summary of results
At baseline, 52% of patients had ≥3 TAMs and 76% had
≥1 non-NRTI mutation. At week 24, 71.4%, 73.3% and
58.3% of patients had HIV-RNA <50 copies/mL in the 600
mg ATC, 800 mg ATC and 150 mg 3TC groups, respec-
tively, with a mean increase in CD4 cells of 145, 211 and
113 cells/μL, respectively, as previously reported. At week
24, all patients switched to open-label ATC. At week 48,
the final results for the three original treatment groups are
shown in Table 1.
There were more ART re-optimisations between day 21
and week 48 in the 3TC arm (7/16) than the 600 mg (2/
17) and 800 mg (2/17) ATC arms. Few changes in HIV
genotype were detected over the 48-week study period,
with no evidence of development of resistance to ATC.
There were no serious adverse events (AEs) related to ATC.
ATC-related AEs were mild or moderate in severity.
Conclusion
ATC provided significant and durable antiviral activity
over the 48-week treatment period, with a favourable
safety profile and no evidence of resistance development.
Sustained and improved responses in viral load and CD4
cells were seen from week 24 to week 48. The greatest
improvements were seen in the 3TC arm: patients switch-
ing from 3TC to ATC at week 24 nearly doubled their CD4
cell increase from week 24 to 48, but still lagged behind
those receiving ATC for the full 48 weeks. Patients receiv-
ing 3TC for the first 24 weeks underwent a greater number
of ART re-optimisations than those receiving ATC. ATC
has the potential to provide significant, very well tolerated
antiviral activity and to enable construction of a potent,
durable regimen in treatment-experienced patients.
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600 mg BID ATC 800 mg BID ATC 150 mg BID 3TC
W48 PP Population n = 13 n = 14 n = 11
% <50 copies/mL 69.2 85.7 90.9
% <400 copies/mL 84.6 92.9 90.9
ΔCD4 cells/μL 261 277 200
% ≥1 log reduction in viral load 84.6 92.9 90.9
Safety Population n = 17 n = 18 n = 16
No. severe AEs 10 13 17
No. SAEs 1 3 5
No. related AEs 3 6 5Page 2 of 2
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